ProAir HFAalbuterol

According to the FDA label: Albuterol tablets, USP are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.

116,674 adverse event reports submitted to the FDA (1995–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with ProAir HFA in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
ProAir HFA adverse event reports by reporter sex
SexReports
Female68,241
Male38,554
Unknown131

By Age Group

View age group data as a table
ProAir HFA adverse event reports by reporter age group
Age groupReports
0-176,737
18-347,438
35-4911,804
50-6422,304
65-7416,380
75+13,911

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included ProAir HFA. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
ProAir HFA adverse event reports by reported outcome
OutcomeReports
Other Serious49,513
Hospitalization42,515
Non-Serious37,189
Death9,816
Life-Threatening5,869
Disability4,092

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for ProAir HFA. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
ProAir HFA adverse event reports by year
YearReports
19951
19982
20032
20042,537
20052,870
20062,338
20072,749
20082,929
20093,173
20104,015
20113,452
20124,612
20133,421
20143,873
20155,288
20165,679
20174,609
20184,802
20194,663
20204,970
20217,054
202210,105
20239,991
202410,179
202510,957
2026 (partial)2,403

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with ProAir HFA

In FDA adverse event reports that mention ProAir HFA, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026